多发性硬化症中的芬戈利莫德:对药物存活率和停药因素的见解
Ana Beatriz Simon-Nogueira1, Arthur Cesario de Holanda1, Rafael Augusto Rosalem1
1Division of Neurology, Hospital das Clínicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, 255 Dr. Enéas Carvalho de Aguiar Avenue, Cerqueira César, São Paulo, SP, 05403-000, Brazil.
Multiple sclerosis and related disorders
|June 22, 2025
概括
在巴西多发性硬化症患者中,Fingolimod的五年药物存活率为50%. 缺乏疗效,特别是复发和放射学发现,是停止治疗的主要原因.
科学领域:
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
- 现实世界的证据.
背景情况:
- 芬戈利莫德是广泛用于治疗多发性硬化症 (MS) 的药物.
- 关于停止使用fingolimod的现实数据对于优化其临床使用至关重要.
- 了解停药率和原因可以改善患者管理.
研究的目的:
- 评估巴西多发性硬化症患者队列中的fingolimod药物存活率.
- 确定与停止使用芬戈利莫德相关的人口和临床因素.
主要方法:
- 在巴西圣保罗,对243名多发性硬化症患者进行了回顾性观察性研究.
- 收集的数据包括人口统计数据,治疗持续时间和停止治疗的原因.
- 进行统计分析以确定显著因素 (p < 0.05).
主要成果:
- 42.8%的患者在平均33个月后停止使用fingolimod.
- 五年药物存活率为50%;一年存活率为84%.
- 缺乏疗效 (复发,放射学发现) 是停止治疗的主要原因 (65%),其次是安全问题 (19%). 年轻的女性患者更有可能停止治疗.
结论:
- 芬戈利莫德在这个巴西队列中显示了五年平均存活率,与国际数据相比.
- 缺乏疗效是停止使用fingolimod的主要驱动因素.
- 患者的特征,如年龄和性别,影响停药,建议个性化治疗方法.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
278
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
278
Factors Affecting Drug Response: Overview
2.4K
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
2.4K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
240
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
240
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
210
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
210
Factors Influencing Drug Absorption: Disease States and Pharmacology
836
Multiple disease states can significantly influence the oral drug absorption process by affecting blood flow and the functionality of the gastrointestinal (GI) system. Various GI diseases, including conditions that alter GI motility, such as diarrhea, decreased acid secretions (achlorhydria), and infections, have been associated with reduced drug absorption.
Substances such as alcohol and specific drugs, including antineoplastics, can also negatively impact drug absorption. For instance,...
Substances such as alcohol and specific drugs, including antineoplastics, can also negatively impact drug absorption. For instance,...
836


